A review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: Evidence review of the clinical benefit and harm

Blockman, MCohen, KDe Waal, RGray, AMaartens, GNel, JParrish, ARees, HReubenson, GKredo, T2025-01-042025-01-042021-07-30https://hdl.handle.net/11288/597990enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/AnticoagulationThromboembolismVenousPulmonary embolismClinical guidelinesA review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: Evidence review of the clinical benefit and harmTechnical Report